Skip to content

Study for the heterogeneity of glioma gene visualization

Radiomics-based visualization of IDH gene heterogeneity in glioma

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000034619
Enrollment
Unknown
Registered
2020-07-12
Start date
2020-07-18
Completion date
Unknown
Last updated
2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioma

Interventions

high light group:stereotactic puncture
darker group:stereotactic puncture

Sponsors

Mao Ying
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-70 years, both male and female; 2. Before the operation, T1 plain scan, t2flair, T1 enhancement, Mrs and DTI were completed. According to the results of magnetic resonance imaging, patients with glioma were initially diagnosed, and they were scheduled to undergo craniotomy in Huashan Hospital without contraindications; 3. Patients who have signed the informed consent form by themselves or their clients; 4. Patients with glioma confirmed by pathology after operation.

Exclusion criteria

Exclusion criteria: 1. Those patients who are going to be admitted for simple biopsy; 2. Patients with severe medical diseases and unable to tolerate surgery during the same period; 3. Patients with bleeding tendency or abnormal coagulation function, or taking aspirin, clopidogrel and other anticoagulants for a long time without stopping taking them; 4. Pregnant and lactating women; 5. Patients who participated in other clinical trials at the same time.

Design outcomes

Primary

MeasureTime frame
IDH mutation;

Countries

China

Contacts

Public ContactMao Ying

Department of Neurosurgery, Huashan Hospital, Fudan University

maoying@fudan.edu.cn+86 13801769152

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026